Five-Drug Antiemetic Combination for Cisplatin Chemotherapy
- 1 January 1992
- journal article
- clinical trial
- Published by Taylor & Francis in Cancer Investigation
- Vol. 10 (3) , 191-199
- https://doi.org/10.3109/07357909209032760
Abstract
A combination of metoclopramide, dexamethasone, droperidol, lorazepam, and diphenhydramine was used in prophylaxis of high-dose (greater than or equal to 100 mg/m2) or moderate dose (greater than or equal to 50 mg/m2) cisplatin. Sixty minutes prior to starting cisplatin, 16 mg dexamethasone, 50 mg diphenhydramine, and 0.5 mg lorazepam were given orally (PO). Droperidol 1 mg was given intramuscularly (IM) 15 minutes prior to beginning cisplatin. Repetitive doses of intravenous (IV) metoclopramide, 2 mg/kg in 75 ml 5% dextrose in water over 15 minutes was given 30 minutes prior to, and at 1 1/2, 4 1/2, and 7 1/2 hours after beginning cisplatin chemotherapy. Only patients with nausea and/or vomiting received subsequent doses of 2 mg/kg metoclopramide IV every 3 hours as needed. Patients refractory to metoclopramide were given 1 mg droperidol IM and 50 mg of diphenhydramine PO every 6 hours. There were 19 men and 9 women with a median age of 58 (range 31-75) years. Complete protection from nausea and vomiting in all courses of treatment occurred in 17 (61%) patients. In 63% and 70% of the 57 evaluable courses, there was neither nausea nor vomiting, during the first 24 hours after cisplatin. When present, nausea was mild and the median number of vomiting episodes was 2 (range 1-3). This antiemetic regimen was well tolerated. Toxicities were mild and occurred in 3 patients (angioneurotic edema, transient episode of facial twitching, and heaviness of tongue, respectively). The 5-drug antiemetic combination can prevent cisplatin-induced nausea and vomiting in a majority of patients.Keywords
This publication has 44 references indexed in Scilit:
- Combination antiemetics for cisplatin chemotherapyCancer, 1988
- Toxicity of FED Chemotherapy in Non-small-Cell Lung CancerAmerican Journal of Clinical Oncology, 1987
- Doxorubicin plus cisplatin in the treatment of apudomasCancer, 1985
- Combination chemotherapy with high-dose methotrexate, bleomycin, and cisplatin in management of head and neck squamous cell carcinomaAmerican Journal of Clinical Oncology, 1985
- ANTIEMETICS: NEUROTRANSMITTER RECEPTOR BINDING PREDICTS THERAPEUTIC ACTIONSThe Lancet, 1982
- Emesis as a Critical Problem in ChemotherapyNew England Journal of Medicine, 1981
- A comparison of the antiemetic effects of droperidol and prochlorperazine in chemotherapy with cis-platinumGynecologic Oncology, 1980
- Cis-Diamminedichloroplatinum, Vinblastine, and Bleomycin Combination Chemotherapy in Disseminated Testicular CancerAnnals of Internal Medicine, 1977
- Cis-diamminedichloroplatinum (II)Annals of Internal Medicine, 1977
- Cancer Treatment Needs Better AntiemeticsNew England Journal of Medicine, 1975